Evaluation of the effect of tofogliflozin on the tissue characteristics of the carotid wall—a sub-analysis of the UTOPIA trial

Naoto Katakami¹*, Tomoya Mita², Norikazu Maeda³, Yasunori Sato⁴, Hirotaka Watada³, Ichiro Shimomura¹ and The UTOPIA Study Investigators

Abstract

Background: Since sodium-glucose cotransporter 2 (SGLT2) inhibitors have a pleiotropic antiatherogenic effect, they are expected to attenuate the progression of atherosclerosis. However, whether SGLT2 inhibitors affect the tissue characteristics of the human arterial wall remains unclear. This study aimed to evaluate the effects of tofogliflozin, a selective SGLT2 inhibitor, on the tissue characteristics of the human arterial wall in type 2 diabetes (T2DM) patients without apparent cardiovascular disease (CVD).

Methods: The present study was a post hoc analysis based on data obtained from the Using Tofogliflozin for Possible Better Intervention against Atherosclerosis for Type 2 Diabetes Patients (UTOPIA) trial, which was a multicenter prospective, randomized, open-label, blinded-endpoint study conducted to evaluate the efficacy of tofogliflozin in preventing the progression of atherosclerosis in patients with T2DM. We evaluated the longitudinal change in the ultrasonic tissue characteristics of the carotid wall using gray-scale median (GSM), an established index of ultrasonic tissue characteristics. The right and left intima-medial areas were delineated, and the GSM values were evaluated (right GSM-CCA and left GSM-CCA). The average values of the right and left carotid arteries were defined as “mean GSM-CCA value.”

Results: In a mixed-effects model for repeated measures, mean GSM-CCA, along with the right and left GSM-CCA values, did not significantly change in either the tofogliflozin (n = 168) or conventional treatment group (n = 169). In addition, the tofogliflozin and conventional treatment groups did not significantly differ regarding the change of the mean GSM-CCA (mean difference [95% CI] −1.24[−3.87, 1.38], P = 0.35), along with the right (mean difference [95% CI] −2.33[−5.70, 1.05], P = 0.18) and the left GSM-CCA (mean difference [95% CI] −0.29[−3.53, 2.95], P = 0.86) values. Similar findings were obtained even after adjusting for traditional cardiovascular risk factors and/or the administration of drugs at baseline.

Conclusions: The tissue characteristics of the carotid arterial wall did not change in either the tofogliflozin or conventional treatment group during the 104-week treatment period, and there was no significant difference between the treatment groups.

Clinical trial registration: UMIN000017607 (https://www.umin.ac.jp/icdr/index.html)

Keywords: Atherosclerosis, Diabetes, Carotid artery, Tissue characteristics, SGLT2 inhibitor, Tofogliflozin

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Since sodium-glucose cotransporter 2 (SGLT2) inhibitors have a pleiotropic antiatherogenic effect, they are expected to attenuate the progression of atherosclerosis. Indeed, several studies have shown that SGLT2 inhibitors attenuate arteriosclerosis in animal models of the disease [1–3]. Furthermore, clinical trials in patients with type 2 diabetes mellitus (T2DM) have shown that SGLT2 inhibitors significantly reduce cardiovascular outcomes [4, 5].

Recently, the Using Tofogliflozin for Possible better Intervention against Atherosclerosis for Type 2 Diabetes Patients (UTOPIA) study, a randomized co Tofogliflozin controlled trial was conducted to investigate the preventive effects of tofogliflozin, an SGLT2 inhibitor, on the progression of carotid intima-media thickness (IMT) in patients with apparent CVD-free T2DM, and found that there were no significant differences in the progression of IMT between the tofogliflozin treatment and conventional treatment [6]. However, whether SGLT2 inhibitors affect the tissue characteristics of the human arterial wall remains unclear.

Presently, various modalities such as ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) are being used to detect vulnerable plaque in coronary and carotid arteries [7–9]. Unfortunately, measurements for carotid atherosclerosis obtained by methods other than ultrasonography were not available for most participants in the UTOPIA study. Recent studies have revealed that noninvasive ultrasonic tissue characterization of carotid plaques using gray-scale median (GSM) reflects plaque composition, and that low-GSM plaques, which consist mainly of lipids, inflammatory infiltrations, and/or hemorrhages, are considered unstable [10]. The aim of the present sub-analysis was to evaluate the effect of tofogliflozin on the longitudinal change in the GSM value, an index of the ultrasonic tissue characteristics of the carotid wall, in patients with T2DM, using data obtained from the UTOPIA trial.

Methods
Study design
The present study was a post hoc analysis based on data obtained from the UTOPIA trial, which was a multicenter prospective, randomized, open-label, blinded-endpoint study conducted to evaluate the efficacy of tofogliflozin in preventing the progression of atherosclerosis in patients with T2DM. The study design, study schedule, and outcomes of the original UTOPIA trial have been described in detail previously [11].

In brief, participants eligible for the study were those who had T2DM in whom the target of blood glucose control specified in the Treatment Guide for Diabetes (edited by the Japan Diabetes Society in 2014–2015) was not achieved (glycated hemoglobin [HbA1c] ≥ 6% but < 9%), despite dietary/exercise therapy or concomitant therapeutic drugs for T2DM other than SGLT2 inhibitors, and those aged 30–74 years at the time of enrollment. Exclusion criteria were (1) presence of type 1 or secondary diabetes; (2) being in the perioperative period or having a serious infection or injury; (3) having a history of myocardial infarction, angina, stroke, or cerebral infarction; (4) an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² or end-stage renal failure, (5) a serious liver functional impairment, (6) moderate to severe heart failure (New York Heart Association stage III or higher), (7) urinary tract or genital infection, (8) being pregnant, possibly pregnant, nursing, or planning to conceive a child; (9) with a history of hypersensitivity to the study drug; (10) presence or history of a malignant tumor (exceptions: patients not on medication for malignant tumor and those without recurrence of the disease and without recurrence risks during this study were allowed to participate), (11) prohibition from using tofogliflozin, and (12) other ineligibility determined by an investigator.

Individuals with CVD-free T2DM who met the above eligibility criteria were asked to participate in this study, and all patients who agreed to participate were enrolled. Originally, a total of 340 patients were enrolled at 22 outpatient diabetes clinics across Japan, and randomly allocated into either the tofogliflozin group (20 mg of tofogliflozin once daily, n = 169) or the conventional treatment group (those using drugs other than the SGLT2 inhibitor) (n = 171).

The protocols of the original study (approval number: N18007, date of approval: 2019/8/7) and this subanalysis (approval number: 19448, date of approval: 2020/3/24) were approved by the Osaka University Clinical Research Review Committee. On the grounds that the current study was a post-hoc analysis using only existing materials, the study was considered exempt from written informed consent of study participants, in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan. Instead, relevant information regarding the study was open to the public, and opportunities for refusal were ensured. The study was conducted in accordance with the Declaration of Helsinki, the Ethical Guidelines for Medical and Health Research Involving Human Subjects, the Clinical Trials Act, and other current legal regulations in Japan.

This study was registered in the University Hospital Medical Information Network Clinical Trials Registry, which is a non-profit organization in Japan that meets the
requirements of the International Committee of Medical Journal Editors (UMIN000017607).

**Ultrasound examination**

B-mode ultrasonography of the carotid artery was performed using an ultrasound machine with a high-frequency linear transducer, according to the guidelines of the Japan Society of Ultrasonics [9]. Scanning of the extracranial common carotid artery (CCA) was performed bilaterally in three different longitudinal projections as well as transverse projections. All scans were electronically stored and sent to the central office for reading by a single experienced reader unaware of the patients’ clinical characteristics in a random order. The IMT was measured as the distance between two parallel echogenic lines corresponding to the blood-intima and media-adventitia interface on the posterior wall of the artery using an automated digital edge-detection software (Intimascope; MediaCross, Tokyo, Japan) [12]. The software system averaged 200 points of IMT values in the segment 2 cm proximal to the dilation of the carotid bulb (mean-IMT-CCA). Localized elevated lesions with a maximum thickness of >1 mm, having a point of inflection on the surface of the intima-media complex, are defined as “carotid plaque” based on the guideline from the Japan Society of Ultrasonics in Medicine [13]. The presence of plaque lesions, the thickness of the plaque lesions (IMT value), and the histological status of plaque lesions (GSM value) were evaluated independently using images taken at three observation time points: baseline, 52 weeks, and 104 weeks.

The echogenicity of the arterial wall was assessed based on the GSM method in a gray-scale range of 0 to 255 (0 as the darkest and 255 as the brightest tone). Adobe Photoshop software (Adobe Systems, version 7.0, San Jose, CA, USA) was used for image standardization and calculation of gray-scale values. In practice, according to a previous report, the standardization of the B-mode image was performed using a curve option so that the GSM for the blood ranged from 0 to 5, and for the adventitia from 185 to 195 [14]. Thus, the gray-scale values of all pixels would change according to the new linear scale defined by the reference values for blood and adventitia, although the ultrasound gain settings for each image were not always standardized. The right and left mean-IMT-CCA areas (intima-media complex of the segment 2 cm proximal to the dilation of the carotid bulb) were then delineated using a freehand tool (shown as a red frame in Fig. 1A), and the GSM values of the selected area were read from the entire delineated area (right GSM-CCA and left GSM-CCA). Subsequently, the average values of the right and left carotid arteries were defined as “mean GSM-CCA.” Similarly, if atherosclerotic plaque lesions or thickened (focal IMT ≥ 1.0 mm) lesions were detected, the GSM values of all these lesions were measured using the same method: the lesions were delineated with a freehand tool (shown as a red frame in Fig. 1B), and the GSM value of each plaque was read from the entire delineated area (GSM-plaque). Subsequently, the lowest value of the right and left carotid arteries were defined as “right GSM-lesion” and “left GSM-lesion,” respectively. Thus, the region size was set for every measurement timing and not standardized across sides and participants.

In this study, repeated GSM measurements were performed in a blinded manner, and the analyses were performed at a core laboratory to avoid bias and measurement errors between institutions, which were electronically stored and sent to the core laboratory for reading by a single experienced reader unaware of the patients’ clinical characteristics in a random order. The same procedure for analyzing carotid GSM values was used in our previous studies [15–17]. Thus, the reliability and reproducibility of the GSM measurements were confirmed in the current study.

**Statistical analysis**

All enrolled patients, except those without baseline GSM measurements, were analyzed. As for baseline and follow-up variables, group comparisons were performed using Student’s t-test or the Wilcoxon rank-sum test for continuous variables and Fisher’s exact test or the chi-square test for categorical variables. Primary analysis was performed using the mixed-effects model for repeated measures (MMRM) with treatment group, time (week), interactions between treatment group and time (week), and baseline GSM as fixed effects; an unstructured covariance was used to model the covariance of within-patient variability. The sensitivity analysis assessed differences in delta change in IMT from baseline between the two groups using analysis of covariance (ANCOVA) models that included treatment group, age, sex, baseline GSM, systolic blood pressure, and administration of statins.

All statistical tests were two-sided, with a 5% significance level. All analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, USA).

**Results**

**Study population**

After excluding three patients from further analysis due to missing data for the primary endpoint, 168 and 169 patients in the tofogliflozin and conventional treatment groups were included in the full analysis set, respectively. At baseline, serum triglyceride (TG) levels were slightly but significantly lower in the tofogliflozin treatment group than in the conventional treatment group. The proportion of patients using DPP-4 inhibitors and
angiotensin II receptor blockers were significantly lower in the tofogliflozin treatment group than in the conventional treatment group. Regarding the other parameters, there were no significant differences in the baseline characteristics between the two groups (Table 1).

Among the study participants, 140 and 146 in the tofogliflozin and conventional treatment groups, respectively, completed the allocated treatment regimen. Reductions in HbA1c, BMI, waist circumference, systolic blood pressure, and urinary albumin excretion during the 104-week treatment period were significantly larger in the tofogliflozin group (n = 168) than in the conventional group (n = 169). There were no significant differences in the changes in serum total, high-density lipoprotein cholesterol (HDLC), and low-density lipoprotein cholesterol, TG levels, and eGFR from baseline to 104 weeks between the two groups (Additional file 1: Table S1).

Over the course of the study, DPP-4 inhibitor use was significantly higher, and after 52 weeks, metformin use was significantly higher in the conventional group than in the tofogliflozin group (Additional file 1: Table S2). Furthermore, antihypertensive drugs, especially angiotensin II receptor blockers (ARBs), were significantly more frequently used, and the use of lipid-lowering agents tended to be higher in the conventional group than in the tofogliflozin group during the study (Additional file 1: Table S3).

**Effect of tofogliflozin on the carotid wall**

At baseline, mean GSM-CCA and left GSM-CCA values were measurable in all the study participants; however, left GSM-CCA values were not measurable in two participants in the tofogliflozin treatment group. Atherosclerotic plaques and/or thickened (focal IMT ≥ 1.0 mm) lesions were observed in the right CCA in 208 patients (99 and 109 in the tofogliflozin and conventional treatment groups, respectively), in the left CCA in 218 patients (107 and 111 in the tofogliflozin and conventional treatment groups, respectively), and in bilateral CCA in 147 patients (65 and 82 in the tofogliflozin and conventional treatment groups, respectively). The GSM values of these plaques were measured, and there were no significant

---

**Fig. 1** Measurement of GSM values. A The right and left mean-IMT-CCA areas (intima-media complex of the segment 2 cm proximal to the dilation of the carotid bulb) were delineated using a freehand tool (shown as a red frame), and the GSM values of the selected area were read from the entire delineated area (“right GSM-CCA” and “left GSM-CCA”). B Similarly, if atherosclerotic plaque lesions or thickened (focal IMT ≥ 1.0 mm) lesions were detected, the GSM values of all these lesions were measured using the same method: the lesions were delineated with a freehand tool (shown as a red frame), and the GSM value of each plaque was read from the entire delineated area (“GSM-plaque”).
| Parameters                                      | Tofogliflozin group (n = 168) | Conventional group (n = 169) | P value |
|------------------------------------------------|------------------------------|-----------------------------|---------|
| Sex (males) (%)                                | 98 (58.3)                    | 98 (58.0)                   | 0.95    |
| Age (years)                                    | 61.4 ± 9.3                   | 60.8 ± 9.7                  | 0.60    |
| Current smoking                                | 38 (22.8)                    | 29 (17.2)                   | 0.20    |
| Body mass index (kg/m²)                        | 27.0 ± 5.8                   | 27.0 ± 4.6                  | 0.98    |
| Waist circumference (cm)                       | 93.1 ± 12.7                  | 93.7 ± 11.7                 | 0.66    |
| Duration of diabetes (years)                   | 12.1 ± 8.4                   | 12.4 ± 8.2                  | 0.75    |
| HbA1c (%)                                      | 7.4 ± 0.7                    | 7.3 ± 0.7                   | 0.22    |
| Fasting blood glucose (mmol/L)                 | 7.8 ± 1.7                    | 7.9 ± 1.8                   | 0.82    |
| Hypertension                                   | 87 (51.8)                    | 104 (61.5)                  | 0.07    |
| Systolic blood pressure (mmHg)                 | 133.0 ± 14.5                 | 134.5 ± 17.4                | 0.39    |
| Diastolic blood pressure (mmHg)                | 77.7 ± 10.0                  | 79.1 ± 11.0                 | 0.23    |
| Total cholesterol (mmol/L)                     | 4.95 ± 0.74                  | 4.93 ± 0.82                 | 0.80    |
| LDL cholesterol (mmol/L)                       | 2.88 ± 0.69                  | 2.89 ± 0.66                 | 0.87    |
| HDL cholesterol (mmol/L)                       | 1.42 ± 0.36                  | 1.37 ± 0.31                 | 0.21    |
| Triglyceride (mmol/L)                          | 1.20 (0.93, 1.78)            | 1.45 (1.00, 1.89)           | 0.049   |
| Diabetic retinopathy                           | 28 (16.9)                    | 33 (19.0)                   | 0.60    |
| Diabetic nephropathy                           | 48 (28.6)                    | 52 (30.8)                   | 0.72    |
| eGFR (mL/min/1.73 m²)                           | 80.8 ± 20.9                  | 81.9 ± 24.1                 | 0.66    |
| Urinary albumin excretion (mg/g/cre)           | 13.0 (6.3, 37.0)             | 17.4 (5.8, 67.9)            | 0.54    |
| Use of glucose-lowering agents                 | 152 (90.5)                   | 151 (89.3)                  | 0.86    |
| Metformin                                      | 91 (54.2)                    | 99 (58.6)                   | 0.44    |
| Sulfonylurea                                    | 38 (22.6)                    | 43 (25.4)                   | 0.61    |
| Glinides                                       | 10 (6.0)                     | 10 (5.9)                    | 1.00    |
| Thiazolidinediones                             | 18 (10.7)                    | 23 (13.6)                   | 0.51    |
| α-Glucosidase inhibitor                        | 24 (14.3)                    | 25 (14.8)                   | 1.00    |
| DPP-4 inhibitors                               | 74 (44.4)                    | 94 (55.6)                   | 0.039   |
| GLP-1 receptor agonists                        | 23 (13.7)                    | 12 (7.1)                    | 0.05    |
| Insulins                                       | 35 (20.8)                    | 36 (21.3)                   | 1.00    |
| Use of antihypertensive drugs                  | 79 (47.0)                    | 95 (56.2)                   | 0.10    |
| Angiotensin-converting enzyme inhibitors        | 3 (1.8)                      | 5 (3.0)                     | 0.72    |
| Angiotensin II receptor blockers               | 63 (37.5)                    | 83 (49.1)                   | 0.037   |
| Direct renin inhibitor                         | 2 (1.2)                      | 0 (0.0)                     | 0.25    |
| Calcium channel blocker                        | 47 (28.0)                    | 54 (32.0)                   | 0.48    |
| Diuretic drugs                                 | 8 (4.8)                      | 14 (8.3)                    | 0.27    |
| α-Adrenergic receptor antagonist               | 2 (1.2)                      | 0 (0.0)                     | 0.25    |
| β-Adrenergic receptor antagonist               | 3 (1.8)                      | 3 (1.8)                     | 1.00    |
| Others                                         | 5 (3.0)                      | 10 (5.9)                    | 0.29    |
| Use of lipid-lowering agents                   | 82 (48.8)                    | 99 (58.6)                   | 0.08    |
| Statins                                        | 73 (43.5)                    | 83 (49.1)                   | 0.33    |
| Ezetimibe                                      | 10 (6.0)                     | 11 (6.5)                    | 1.00    |
| Resins                                         | 0 (0.0)                      | 1 (0.6)                     | 1.00    |
| Fibrates                                       | 8 (4.8)                      | 6 (3.6)                     | 0.60    |
| Use of antithrombotic agents                   | 17 (10.1)                    | 14 (8.3)                    | 0.58    |
| Antiplatelet agents                            | 15 (8.9)                     | 10 (5.9)                    | 0.31    |
| Anticoagulants                                 | 2 (1.2)                      | 4 (2.4)                     | 0.68    |
| Others                                         | 0 (0.0)                      | 0 (0.0)                     | –       |

Data are presented as number (%) of patients or mean ± SD values or median (25th and 75th percentiles) values

HbA1c: glycated hemoglobin, SD: standard deviation, LDL: low-density lipoprotein, HDL: high-density lipoprotein, DPP-4: dipeptidyl peptidase-4, GLP-1: glucagon-like peptide-1
differences in any of the GSM measures (i.e., mean GSM-
CCA, right GSM-CCA, left GSM-CCA, right GSM-
lesion, and left GSM-lesion) between the two treatment
groups at baseline (Table 2).

Both the tofogliflozin treatment and conventional treat-
ment groups did not show significant effects on the mean
GSM-CCA values (from 38.07±12.49 to 37.32±12.86
and 38.42±14.19 to 38.63±14.80, respectively), right
GSM-CCA values (from 37.91±14.36 to 36.06±13.84
and 37.90±15.82 to 38.33±15.75, respectively), and left
GSM-CCA values (from 38.06±13.93 to 38.48±15.24
and 38.94±15.44 to 38.84±16.53, respectively) during
the 104-week observation period. There was also no sig-
nificant difference in right- and left-GSM-lesion values
between both groups (Table 2).

The magnitude of the change in GSM values between
the two treatment groups during the treatment period
was compared using the MMRM (Table 2). These analy-
ses also revealed that neither tofogliflozin treatment nor
conventional treatment significantly changed any of the
GSM measures. In addition, there was no significant dif-
fERENCE in the change in GSM measures from baseline to
week 52 and week 104, between the two groups. Similar
findings were observed even after adjustment for possible
confounding factors such as age, sex, BMI, HbA1c, serum
lipid levels (e.g., total cholesterol, HDLC, and TG), blood
pressure, smoking status, and administration of anti-dia-
betic, anti-hypertensive, anti-hyperlipidemic, and anti-
platelet drugs (Table 3).

Regarding the effect of tofogliflozin on mean-IMT-
CCA, the results were similar to those observed in the
original UTOPIA trial: we confirmed statistically signifi-
cant IMT reduction in both the tofogliflozin treatment
and the control groups, and that there were no signifi-
cant differences in the progression in mean-IMT-CCA
between the two treatment groups (Table 2).

In addition, we have added a sub-analysis, where the
changes of GSM-CCA were compared among the three
groups based on tertiles of changes in mean-IMT during
the treatment period. This analysis also showed no signif-
icant differences in the mean GSM-CCA from baseline to
week 104 among them (Additional file 1: Table S4). Simi-
lar results were observed in the analyses where the study
participants were divided into the tofogliflozin treatment
group and the conventional treatment group (Additional
file 1: Table S4).

Discussion
Several previous studies have shown that SGLT2 inhibi-
tors, such as empagliflozin and canagliflozin, attenuated
arteriosclerosis in mouse models of atherosclerotic dis-
eease [1–3]. In addition, it has been reported that carotid
IMT reduced after treatment with SGLT2 inhibitors in
patients with T2DM [6, 18]. However, whether SGLT2
inhibitors affect the tissue characteristics of the arterial
wall remains unclear. Therefore, using data obtained from
the UTOPIA trial, a randomized controlled trial con-
ducted to investigate the preventive effects of tofoglifo-
zin on the progression of carotid IMT in patients with
apparent CVD-free T2DM, we evaluated the longitudi-
nal change in the ultrasonic tissue characteristics of the
carotid wall and found that tofogliflozin treatment did
not significantly affect the tissue characteristics of the
carotid wall.

Notably, the original study clearly demonstrated that
carotid IMT significantly reduced after 104 weeks of
tofogliflozin treatment, while there were no significant
differences in the reduction in IMT between the two
treatment groups [6].

One possible explanation for this discrepancy between
the effect of tofogliflozin on carotid IMT and that on
GSM is that the determinants of arterial thickening in
the carotid and those of the tissue characteristics of the
carotid wall are not the same. Many studies have shown
that HbA1c and blood pressure, as well as male sex, age,
BMI, and serum HDLC levels are major risk factors for
carotid IMT progression [19–22]. On the other hand,
our previous study revealed that low HDLC levels and
high BMI were major determinants of low GSM val-
ues in patients with diabetes and that HbA1c and blood
pressure levels were not associated with carotid GSM
[23]. Similarly, Andersson et al. reported that HDLC and
BMI were independent determinants of carotid GSM,
while blood pressure, smoking, and BMI were inde-
pendent determinants of carotid IMT [24]. Generally,
lipid oxidation and inflammation, rather than hypergly-
cemia and hypertension, are considered the most criti-
cal determinants of arterial echogenicity [25–27]. In our
study, reductions in HbA1c and systolic blood pressure
levels as well as a reduction in BMI and an elevation of
HDLC levels were observed in the tofogliflozin treat-
ment group (Additional file 1: Table S1). It is possible
that such a broad and potent effect of tofogliflozin on the
major determinants of carotid IMT, including hypergly-
cemia and hypertension, as well as dyslipidemia, induced
a substantial reduction of IMT. However, the relatively
small effect of tofogliflozin on the lipid-related para-
eters was not enough to induce a change in the tissue
characteristics.

It is also possible that the beneficial effects of tofoglifo-
zin on the tissue characteristics of the carotid wall, if any,
was masked by the administration of additional antdia-
betic, antilipidemic, and antihypertensive agents, which
are supposed to affect the tissue characteristics of the
arterial wall. In particular, lipid-lowering agents have a
potent anti-atherogenic effect and have been reported
Table 2  Effects of tofogliflozin on gray-scale median values

|                  | Tofogliflozin group | Conventional group | Treatment effect (tofogliflozin-conventional treatment) mean change (95% CI), P value | P value between groups |
|------------------|---------------------|--------------------|--------------------------------------------------------------------------------------|-----------------------|
| **Mean GSM-CCA** |                     |                    |                                                                                      |                       |
| Baseline         | 38.07 ± 12.49 (n = 168) | 38.42 ± 14.19 (n = 169) | 0.081                                                                                |                       |
| Week 52          | 38.09 ± 12.01        | 39.49 ± 14.29      | 0.035                                                                                |                       |
| Week 104         | 37.32 ± 12.86        | 38.63 ± 14.80      | 0.042                                                                                |                       |
| Change at Week 52| −0.38 ± 12.02       | 1.03 ± 11.58       | −1.40 (−4.03, 1.23), P = 0.30                                                       |                       |
| Change at Week 104| −0.98 ± 11.15      | 0.26 ± 11.90       | −1.24 (−3.87, 1.38), P = 0.35                                                       |                       |
| **Right GSM-CCA**|                     |                    |                                                                                      |                       |
| Baseline         | 37.91 ± 14.36 (n = 168) | 37.90 ± 15.82 (n = 169) | 0.99                                                                                |                       |
| Week 52          | 38.01 ± 14.21        | 39.37 ± 17.12      | 0.45                                                                                |                       |
| Week 104         | 36.06 ± 13.84        | 38.33 ± 15.75      | 0.19                                                                                |                       |
| Change at Week 52| −0.07 ± 16.25       | 1.45 ± 17.47       | −1.52 (−5.29, 2.26), P = 0.43                                                       |                       |
| Change at Week 104| −1.80 ± 14.35      | 0.52 ± 15.22       | −2.33 (−5.70, 1.05), P = 0.18                                                       |                       |
| **Left GSM-CCA** |                     |                    |                                                                                      |                       |
| Baseline         | 38.06 ± 13.93 (n = 166) | 38.94 ± 15.44 (n = 169) | 0.58                                                                                |                       |
| Week 52          | 38.26 ± 13.27        | 39.50 ± 16.22      | 0.46                                                                                |                       |
| Week 104         | 38.48 ± 15.24        | 38.84 ± 16.53      | 0.85                                                                                |                       |
| Change at Week 52| −0.40 ± 13.66       | 0.44 ± 13.6        | −0.85 (−3.84, 2.14), P = 0.58                                                       |                       |
| Change at Week 104| −0.06 ± 14.50      | 0.23 ± 13.81       | −0.29 (−3.53, 2.95), P = 0.86                                                       |                       |
| **Right GSM-lesion** |                   |                    |                                                                                      |                       |
| Baseline         | 47.53 ± 25.71 (n = 99) | 48.43 ± 22.65 (n = 109) | 0.79                                                                                |                       |
| Week 52          | 48.55 ± 26.02        | 49.83 ± 24.42      | 0.92                                                                                |                       |
| Week 104         | 46.70 ± 24.00        | 49.92 ± 24.12      | 0.36                                                                                |                       |
| Change at Week 52| 1.33 ± 24.69        | −0.83 ± 25.66      | 2.15 (−5.20, 9.50), P = 0.56                                                       |                       |
| Change at Week 104| 0.37 ± 27.09        | 2.01 ± 28.34       | −1.64 (−10.01, 6.73), P = 0.70                                                       |                       |
| **Left GSM-lesion** |                   |                    |                                                                                      |                       |
| Baseline         | 47.93 ± 23.29 (n = 107) | 48.24 ± 23.96 (n = 111) | 0.92                                                                                |                       |
| Week 52          | 50.76 ± 27.66        | 46.30 ± 24.60      | 0.23                                                                                |                       |
| Week 104         | 47.83 ± 22.64        | 47.65 ± 21.48      | 0.95                                                                                |                       |
| Change at Week 52| 4.31 ± 25.42        | −2.68 ± 25.85      | 6.99 (−0.34, 14.32), P = 0.06                                                       |                       |
| Change at Week 104| 1.33 ± 21.36        | −0.14 ± 22.96      | 1.47 (−4.98, 7.92), P = 0.65                                                       |                       |
| **Common mean-IMT-CCA** |               |                    |                                                                                      |                       |
| Baseline         | 0.87 ± 0.16 (n = 168) | 0.86 ± 0.15 (n = 169) | 0.93                                                                                |                       |
| Week 52          | 0.79 ± 0.14          | 0.78 ± 0.13        | 0.76                                                                                |                       |
| Week 104         | 0.74 ± 0.14          | 0.72 ± 0.13        | 0.48                                                                                |                       |
| Change at Week 52| −0.085 ± 0.0715      | −0.085 ± 0.0675     | 0.001 (−0.012, 0.015), P = 0.84                                                    |                       |
| Change at Week 104| −0.136 ± 0.0915     | −0.142 ± 0.0895    | 0.008 (−0.009, 0.025), P = 0.35                                                    |                       |
| **Right mean-IMT-CCA** |               |                    |                                                                                      |                       |
| Baseline         | 0.84 ± 0.15 (n = 168) | 0.85 ± 0.15 (n = 169) | 0.84                                                                                |                       |
| Week 52          | 0.77 ± 0.13          | 0.77 ± 0.14        | 0.96                                                                                |                       |
| Week 104         | 0.72 ± 0.13          | 0.72 ± 0.14        | 0.76                                                                                |                       |
| Change at Week 52| −0.074 ± 0.0765      | −0.077 ± 0.0745     | 0.003 (0.013, 0.018), P = 0.74                                                    |                       |
| Change at Week 104| −0.124 ± 0.0925     | −0.131 ± 0.0865    | 0.007 (0.011, 0.025), P = 0.46                                                    |                       |
| **Left mean-IMT-CCA** |               |                    |                                                                                      |                       |
| Baseline         | 0.89 ± 0.20 (n = 168) | 0.88 ± 0.19 (n = 169) | 0.76                                                                                |                       |
| Week 52          | 0.80 ± 0.18          | 0.79 ± 0.17        | 0.66                                                                                |                       |
| Week 104         | 0.75 ± 0.19          | 0.73 ± 0.17        | 0.38                                                                                |                       |
| Change at week 52| −0.096 ± 0.1025      | −0.094 ± 0.0923     | 0.001 (0.019, 0.020), P = 0.95                                                    |                       |
| Change at week 104| −0.148 ± 0.1275     | −0.153 ± 0.1075    | 0.010 (0.013, 0.033), P = 0.41                                                    |                       |

Data are presented as the mean ± SD unless stated otherwise. Comparisons of GSM values during treatment with those at baseline were performed using a one-sample t-test based on the mixed-effects model for repeated measures. *P < 0.05, **P < 0.01, ***P < 0.001. Differences in GSM (or IMT) between groups at each point and delta change in GSM (or IMT) from baseline to week 52 and 104 between groups at each point (treatment effect) were analyzed using Student’s t-test.

CCA common carotid artery, GSM Gray-Scale Median, IMT intima-media thickness
to improve the tissue characteristics of plaques in the carotid artery [28–30]. Notably, the administration rate of lipid-lowering agents during the treatment period was relatively higher in the conventional treatment group than in the tofogliflozin treatment group; the proportions of lipid-lowering agent users were 48.8% and 58.6% in the tofogliflozin and conventional treatment groups at baseline (p = 0.08), respectively, and 52.9% and 63.2% at 104 weeks (p = 0.08), respectively (Additional file 1: Table S3). Such an uncontrolled imbalance in the administration of lipid-lowering agents might have masked the potential beneficial effects of tofogliflozin. Similarly, it is possible that the administration of DPP-4 inhibitors, which was more frequent in the control group during the treatment period (Additional file 1: Table S2), may have affected the outcomes, since DPP-4 inhibitors also affect the tissue characteristics of the carotid artery [15, 16].

Peppa-Patrikiou et al. reported an increase in carotid IMT in participants with insulin-dependent diabetes mellitus and that IMT was positively related to urinary free cortisol in this population. Their findings indicated that hyperactivity of the adrenals might contribute to macroangiopathy via mechanisms such as stress, hyperglycemic episodes, and increased endothelin production [31]. Other researchers have also reported that the progression of carotid atherosclerosis was associated with serum or urinary cortisol levels [32–34]. Interestingly, a recent study revealed that administration of tofogliflozin decreased both serum ACTH and cortisol levels in patients with T2DM, indicating that tofogliflozin influences the hypothalamic–pituitary–adrenal pathway in this population [35]. Therefore, SGLT2 inhibitors may be related to the attenuation of carotid atherosclerosis via reduction of serum cortisol levels. However, it is unclear whether the effects of tofogliflozin on carotid IMT and GSM could be explained by the serum cortisol level since it was not measured in the UTOPIA trial.

Our study has some limitations. First, this was a post-hoc analysis using data obtained from the UTOPIA trial. It might have lacked the power to detect a smaller effect, which might be the reason why this study did not show a significant difference between the two treatment groups. Prespecified studies with large sample size would be necessary to confirm our findings. Second, the diagnostic performance of ultrasonography is limited due to a user-dependent methodology; however, ultrasonography represents the first-line imaging modality in the evaluation of carotid artery plaques since it is relatively simple, inexpensive, and widely available. Recent advances in medical imaging have enabled noninvasive identification of the characteristics of the carotid wall using other modalities. For example, high-resolution MRI has been used to evaluate the characteristics of carotid atherosclerotic plaques with high accuracy [36], despite being complex, expensive, and less readily available than other imaging modalities. Multi detector CT scanners (MDCT), which enable fast and accurate acquisition of vascular structures with minimal discomfort to the patient, can provide comparable results in the detection of soft tissue subcomponents of the plaque when compared to MRI [37–39]; however, MDCT has also the limitations such as renal toxicity related to the use of contrast medium, radiation exposure, and artifacts. F-18-fluorodeoxyglucose (FDG)-PET can illuminate metabolically active processes and distinguish vulnerable from non-vulnerable plaques, although it does require longer procedural times than other imaging options. In the UTOPIA study, the measurements for carotid atherosclerosis obtained by modalities such as MRI, MDCT, or FDG-PET were not available for most participants. Third, the ultrasound settings for each image were not always standardized. However, the blood was used as the reference for black and the adventitia as the reference for white, and gain settings for measurements within an individual were similar throughout the study. Therefore, the impact of the gain of the ultrasound beam on the GSM value would be quite small, if any. Fourth, regarding the assessment of mean-GSM-CCA, the same regions were measured throughout the study in each patient. However, regarding the assessment of plaque lesions, this study evaluated the effect of tofogliflozin administration on the histological status of plaque lesions on a patient-by-patient basis using those lesions with the highest risk at each observation point as the representative value for the given patient. Therefore, the plaque lesions evaluated at the three observation time points (baseline, 52 weeks, and 104 weeks) are not necessarily always the same, and due to the inability to track changes in individual plaque lesions over time, it is possible that the effect of tofogliflozin administration on the histological status of plaque lesions could not be appropriately evaluated. Fifth, the administrations of anti-diabetic, anti-hyperlipidemic, and anti-hypertensive drugs, which may affect the plaque components, were not matched completely. It is possible that the inhibition of atherosclerotic change following tofogliflozin treatment might have been masked by the analogous effects of other drugs used in managing diabetes, as described above. Finally, the participants in this study were Japanese patients with T2DM, a cohort with relatively low cardiovascular risk. Therefore, it would be premature to generalize our findings to other racial or ethnic groups.
Table 3  Effects of tofogliflozin on the GSM values of common carotid arteries after adjusting for confounders

|                         | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | Model 6 | Model 7 |
|-------------------------|---------|---------|---------|---------|---------|---------|---------|
| **Mean GSM-CCA**        |         |         |         |         |         |         |         |
| Week 52                 | −1.43 (−3.78, 0.91) | −1.40 (−3.75, 0.94) | −1.80 (−4.23, 0.63) | −2.00 (−4.46, 0.47) | −2.13 (−4.60, 0.33) | −1.86 (−4.33, 0.60) | −1.88 (−4.38, 0.62) |
| Week 104                | −1.19 (−3.59, 1.22) | −1.16 (−3.57, 1.26) | −1.03 (−3.49, 1.43) | −1.21 (−3.68, 1.25) | −1.36 (−3.83, 1.10) | −1.08 (−3.56, 1.41) | −1.12 (−3.64, 1.41) |
| **Right GSM-CCA**       |         |         |         |         |         |         |         |
| Week 52                 | −1.55 (−4.79, 1.68) | −1.48 (−4.71, 1.75) | −1.76 (−5.14, 1.61) | −2.15 (−5.58, 1.27) | −2.30 (−5.74, 1.13) | −1.98 (−5.42, 1.46) | −2.30 (−5.75, 1.14) |
| Week 104                | −2.13 (−5.02, 0.76) | −2.06 (−4.95, 0.83) | −1.89 (−4.88, 1.09) | −2.25 (−5.24, 0.75) | −2.40 (−5.39, 0.59) | −2.07 (−5.08, 0.94) | −2.45 (−5.49, 0.60) |
| **Left GSM-CCA**        |         |         |         |         |         |         |         |
| Week 52                 | −1.07 (−3.75, 1.61) | −1.10 (−3.79, 1.58) | −1.54 (−4.35, 1.26) | −1.69 (−4.55, 1.17) | −1.81 (−4.66, 1.04) | −1.54 (−4.39, 1.31) | −1.29 (−4.19, 1.61) |
| Week 104                | −0.40 (−3.38, 2.59) | −0.43 (−3.42, 2.57) | −0.26 (−3.33, 2.82) | −0.39 (−3.48, 2.70) | −0.54 (−3.63, 2.56) | −0.26 (−3.36, 2.85) | −0.02 (−3.15, 3.11) |
| **Right GSM-lesion**    |         |         |         |         |         |         |         |
| Week 52                 | 1.32 (−4.81, 7.45) | 1.34 (−4.80, 7.48) | 0.01 (−6.31, 6.34) | −0.74 (−7.18, 5.70) | 0.61 (−7.07, 5.84) | 0.01 (−6.46, 6.47) | −0.04 (−6.98, 5.99) |
| Week 104                | −2.68 (−9.58, 4.22) | −2.63 (−9.52, 4.26) | −3.30 (−10.51, 3.91) | −4.02 (−11.33, 3.30) | −3.90 (−11.28, 3.47) | −3.27 (−10.48, 3.94) | −3.81 (−10.94, 3.32) |
| **Left GSM-lesion**     |         |         |         |         |         |         |         |
| Week 52                 | 5.77 (−0.67, 12.22) | 5.83 (−0.50, 12.16) | 5.83 (−0.73, 12.38) | 6.18 (−0.57, 12.93) | 5.76 (−1.07, 12.59) | 5.83 (−0.87, 12.53) | 6.58 (−0.27, 13.44) |
| Week 104                | 0.83 (−4.73, 6.39) | 1.03 (−4.53, 6.60) | 0.67 (−5.00, 6.34) | 0.99 (−4.86, 6.85) | 0.54 (−5.40, 6.49) | 0.61 (−5.20, 6.43) | 1.45 (−4.40, 7.30) |

Treatment effect (tofogliflozin and conventional treatment) is expressed as the mean change (95% CI). Differences in delta change in GSM from baseline at 52 and 104 weeks between groups at each point (treatment effect) were analyzed using a mixed-effects model for repeated measures. *P < 0.05, †P < 0.01, ‡P < 0.001

Model 1: treatment group, week, interactions between treatment groups and week, and baseline GSM were included as fixed effects. Model 2: model 1 plus sex and age were included as fixed effects

Model 3: model 2 plus body mass index, HbA1c, total cholesterol, high-density lipoprotein-cholesterol, triglyceride, and systolic blood pressure at baseline were included as fixed effects

Model 4: model 3 plus smoking, DPP-4 inhibitors, and angiotensin II receptor blockers at baseline were included as fixed effects

Model 5: model 4 plus statin and anti-platelets at baseline were included as fixed effects

Model 6: model 3 plus smoking, hypoglycemic agents, antihypertensive agents, antihyperlipidemic agents, and antiplatelets at baseline were included as fixed effects

Model 7: model 3 plus smoking, metformin, sulfonylureas, glinides, pioglitazone, α-glucosidase inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, antihypertensive agents, antihyperlipidemic agents, and antiplatelets at baseline were included as fixed effects

CCA common carotid artery, GSM Gray-Scale Median
Conclusions
In conclusion, this post hoc sub-analysis suggests that the tissue characteristics of the carotid arterial wall did not change in either the tofogliflozin treatment group or conventional treatment group during the 104-week treatment period and that there was no significant difference between the treatment groups.

Abbreviations
ANOVA: Analysis of covariance; BMI: Body mass index; CVD: Cardiovascular disease; CVOT: Cardiovascular outcome trial; DPP-4: Dipeptidyl peptidase-4; eGFR: Estimated glomerular filtration rate; HbA1c: Glycated hemoglobin; HDLC: High-density lipoprotein cholesterol; IMT: Intima-media thickness; SGLT2: Sodium-glucose cotransporter 2; UTOPIA: Using tofogliflozin for possible better intervention against atherosclerosis for type 2 diabetes patients.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01451-6.

Additional file 1: Tables S1. Between-group comparison of changes in clinical parameters during the treatment period. Table S2. Changes in concomitantly used anti-diabetic agents. Table S3. Changes in concomitantly used cardiovascular medications. Table S4. The changes of GMS-CCA on the basis of tertiles of changes in mean-IMT during observation period.

Acknowledgements
The authors thank all the staff and patient participants for this study. The authors gratefully acknowledge the assistance of K Ando in performing GMS analysis and H Yamada and D Takayama (Soiken Holdings Inc., Tokyo, Japan) for performing statistical analysis and Editage (www.editage.com) for English language editing.

Authors’ contributions
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors read and approved the final manuscript.

Funding
Financial support for this study, including the fees for the assistance and processing of the article by the journal, was provided by Kowa Co., Ltd., Tokyo, Japan.

Availability of data and materials
The datasets generated and/or analyzed during our study will be available from the corresponding author upon reasonable request.

Declarations
Ethics approval and consent to participate
All procedures followed were in accordance with the ethical standards of the appropriate committee on human experimentation (in institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all the patients for inclusion in the study.

Consent for publication
Not applicable.

Competing interests
Naoto Katakami is a staff member of the endowed chair established by funds from Kowa Co., Ltd., and has received research funds from MSD, and lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim, Daiichi Sankyo Inc., Eli Lilly, Kowa Pharmaceutical Co., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Taisho Toyama Pharmaceutical Co., Takeda Pharmaceutical Co., and Sanofi-Aventis, and Shionogi & Co. Ltd.

Tomoya Mita has received lecture fees from Astellas Pharma Inc., Daichi Sankyo Inc., Eli Lilly, Kowa Pharmaceutical Co., Kyowa Hakko Kirin Co. Ltd., Mitsubishi Tanabe Pharma Co., Novo Nordisk Pharma, Ono Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited and Sanofi-Aventis, scholarship donations from MSD K.K., Astellas Pharma Inc., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co. Ltd., Novo Nordisk Pharma K.K., Takeda Pharmaceutical Company Limited, and Sanofi-Aventis K.K., Daiichi Sankyo Company Limited, Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Company Limited, Mitsubishi Tanabe Pharma Corporation, Terumo Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., Benefit One Health Care Inc., Medichica Pharmaceutical Co., Ltd., and Nitto Boseki Co., Ltd. as well as funds of endowed chair from MSD K.K., Takeda Pharmaceutical Company Limited.

Nonkazu Maeda is a staff member of the endowed chair established by funds from Kowa Co., Ltd., Teijin Pharma Co., Ltd., and Mitsubishi Tanabe Pharma Co., Ltd., and lecture fees from Astellas Pharma Inc., AstraZeneca K.K., Boehringer Ingelheim, Eli Lilly Japan K.K., Kowa Co., Ltd., Mitsubishi Tanabe Pharma Co., Ltd., Novartis Pharmaceuticals, Novo Nordisk Pharma, Ono Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., and Yakult Honsha Co., Ltd.

Yukitomo Ono has received lecture fees from Mochida Pharmaceutical Co., Ltd., Hirotaka Watada has received lecture fees from Sumitomo Dainippon Pharma Co., Ltd., Bayer Yakuhin, Ltd., Sanofi-Aventis K.K., MSD K.K., Astellas Pharma Inc., Takeda Pharmaceutical Company Ltd., Mitsubishi Tanabe Pharma Co., AstraZeneca K.K., Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Kowa Co., Ltd., Novartis Pharmaceuticals Corp., Daiichi Sankyo Company, Ltd., Kyowa Hakko Kirin Co. Ltd., Ono Pharmaceutical Co., Ltd., and Kissei Pharmaceutical Co., Ltd. and research support from Novartis Pharmaceuticals Corp., Otsuka Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Kowa K.K., Astellas Pharma Inc., Bayer Yakuhin, Ltd., Teijin Pharma Ltd., Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Sanofi-Aventis K.K., Sanwa Kagaku Kenkyusho Co., Ltd., Daiichi Sankyo Company, Ltd., Sumitomo Dainippon Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., and Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Novo Nordisk Pharma Ltd., Pfizer Japan Inc., Shionogi & Co., Ltd., Yakult and Kissei Pharmaceutical Co., Ltd.

Ichiro Shimomura has received lecture fees from Astellas Pharma Inc., AstraZeneca K.K., MSD K.K., Ono Pharmaceutical Co., Kowa Co., Ltd., Kowa Company, Ltd., Sanofi K.K., Sanwa Kagaku Kenkyusho Co., Daichi Sankyo Co., Takeda Pharma K.K., Mitsubishi Tanabe Pharma Co., Teijin Pharma, Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Novartis Pharma K.K., Novo Nordisk Pharma, Mochida Pharmaceutical Co., Taisho Pharmaceutical Co. Ltd., Novo Nordisk Pharma, Ono Pharmaceutical Co., Ltd., Coviden Japan Inc., Amgen Astellas Biopharma K.K., KOBAIYASHI Pharmaceutical Co., Ltd., Dainippon Sumitomo Pharma Co., Rohto Pharmaceutical Co., Ltd., and research funds from Astellas Pharma Inc., MSD K.K, Ono Pharmaceutical Co., Kaken Pharmaceutical Co., Kyowa Kirin Co. Ltd., Sanofi K.K., Shionogi & Co., Daiichi Sankyo Co., Dainippon Sumitomo Pharma Co., Takeda Pharma K.K., Mitsubishi Tanabe Pharma Co, Teijin Pharma, Novartis Pharma K.K., Novo Nordisk Pharma, Eli Lilly Japan K.K, Kowa Company, Ltd., and consulting fees from AstraZeneca K.K., MSD K.K, Taisho Pharmaceutical Co. Ltd, Novo Nordisk Pharma, Lotte Co., Ltd.

Author details
1. Department of Preventive Medicine and Public Health, Keio University School of Medicine, 45 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan.
2. Department of Metabolic Medicine, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. 3. Department of Metabolic & Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. 4. Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. 5. Department of Metabolism & Endocrinology, Juntendo University Graduate School of Medicine, Hongo 2-1-1, Bunkyo-ku, Tokyo 113-8421, Japan. 6. Department of Preventive Medicine and Public Health, Keio University School of Medicine, 45 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan.

Received: 17 November 2021 Accepted: 25 January 2022
Published online: 05 February 2022
References

1. Lin B, Koibuchi N, Hasegawa Y, Suet a D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.

2. Han JH, Oh TJ, Lee G, Maeng HJ, Lee DH, Kim KM, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in Apoe- mice fed a western diet. Diabetologia. 2017;60:364–76.

3. Nasir-Arani N, Dimitriadis GK, Agrogiannis G, Perrea D, Kostakis I, Kaltas G, et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in Apoe knockout mice. Cardiovasc Diabetol. 2018;17:106.

4. Zinnerman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(217–28):2637/978.

5. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erduz N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–57.

6. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al. Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study. Cardiovasc Diabetol. 2020;19:110. https://doi.org/10.1186/s12933-020-01079-4.

7. Nishio M, Ueda Y, Matsuo K, Asai M, Nemoto T, Hirata A, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J. 2007;28:2243–8.

8. Hatsuoka TS, Ross R, Polisar NL, Yuan C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation. 2000;102:959–64.

9. Grønholdt ML, Wiebe BM, Laursen H, Nielsen TG, Schroeder TV, Sillesen H. Lipid-rich carotid artery plaques appear echolucent on ultrasound B-mode images and may be associated with intraplaque haemorrhage. Eur J Vasc Endovasc Surg. 1997;14:439–45.

10. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yusa da T, Okada Y, et al. Rationale, design, and baseline characteristics of the UTOMIA trial for preventing diabetic atherosclerosis using an SGLT2 inhibitor: a prospective, randomized, open-label, parallel-group comparative study. Diabetes Ther. 2017;8:999–1013.

11. Yanase T, Nasiri-Ansari N, Suyama H, Shimizu Y, Nishihara T, Okabe T, et al. Detection of disrupted plaques by coronary CT: comparison with angiography. Heart. 2011;97:1397–402.

12. Tahara N, Kai H, Naka hura H, Mizoguchi M, Ishibashi M, Kaida H, et al. The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography. Eur Heart J. 2007;28:2243–8.

13. Matsumoto T, Yokoyama H, Hasegawa Y, Sueta D, Toyama K, Uekawa K, et al. Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice. Cardiovasc Diabetol. 2014;13:148.

14. Yanase T, Nasu S, Muku t a Y, Shimizu Y, Nishihara T, Okabe T, et al. Evaluation of a new carotid intima-media thickness measurement by B-mode ultrasonography using an innovative measurement software, intimascope. Am J Hypertens. 2006;19:1206–12.

15. Terminology and diagnostic criteria committee, Japan Society of Ultrasound in Medicine. Subcommittee for preparing guidelines for ultrasound diagnosis of carotid artery standard method for ultrasound evaluation of carotid artery lesions. Jpn J Med Ultrason. 2009;36:501–18.

16. Sabetai M, Tegos TJ, Nicolaides AN, Dhanji S, Pare GJ, Stevens JM. Reproducibility of computer-quantified carotid plaque echogenicity: can we overcome the subjectivity? Stroke. 2000;31:2189–96.

17. Irie Y, Katakami N, Mita T, Takahara M, Matsueka TA, Goshio M, et al. Study of preventive effects of alogliptin on diabetic atherosclerosis (SPEAD-A) collaborators. Evaluation of the effect of alogliptin on tissue characteristics of the carotid wall: sub-analysis of the SPEAD-A trial. Diabetes Ther. 2018;9(1):317–29.

18. Irie Y, Katakami N, Mita T, Takahara M, Matsueka TA, Goshio M, et al. Effect of sitagliptin on tissue characteristics of the carotid wall in patients with type 2 diabetes—a post hoc sub-analysis of the sitagliptin preventive study of intima-media thickness evaluation (SPIKE). Cardiovasc Diabetol. 2018. https://doi.org/10.1186/s12933-018-0666-3.

19. Nakamura T, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, et al. Effects of tofogliflozin on adrenocorticotropic hormone, renin and cortisol levels in elderly patients with diabetes mellitus: a retrospective study of a patient cohort. Med (Baltimore). 2021;100:7638.

20. Murgul MM, Khan MK, DeMarco JK, Majid A, Shamoun F, Abela GS. Symptomatic and asymptomatic carotid artery plaque. Expert Rev Cardiovasc Ther. 2011;9:1315–30.
37. Wintermark M, Jawadi SS, Rapp JH, Tihan T, Tong E, Glidden DV, et al. High-resolution CT imaging of carotid artery atherosclerotic plaques. Am J Neuroradiol. 2008;29:875–82.

38. Saba L, Mallanini G. Fissured fibrous cap of vulnerable carotid plaques and symptomaticity: are they correlated? Preliminary results by using multi-detector-row CT angiography. Cerebrovasc Dis. 2009;27:322–7.

39. Saba L, Micheletti G, Brinjikji W, Garofalo P, Montisci R, Balestrieri A, et al. Carotid intraplaque-hemorrhage volume and its association with cerebrovascular events. Am J Neuroradiol. 2019;40:1731–7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.